Abstract 316TiP
Background
Phase 2 studies (NCT02296684 and NCT02641093) with neoadjuvant and adjuvant pembro have demonstrated pathological response (PR) and acceptable safety in pts with high-risk resectable LA HNSCC. The randomized, global, open-label, phase 3 KEYNOTE-689 trial (NCT03765918) will evaluate the efficacy and safety of neoadjuvant pembro and adjuvant pembro plus SOC in pts with previously untreated resectable LA HNSCC.
Trial design
Pts will be randomly assigned 1:1 to two arms. In arm A, pts will receive neoadjuvant pembro (200 mg Q3W, 2 cycles), followed by surgical resection, then SOC plus adjuvant pembro (200 mg Q3W, 15 cycles). In arm B, pts will undergo surgical resection followed by adjuvant SOC without pembro. SOC is radiotherapy (RT) alone (pts at low risk) or RT plus concurrent cisplatin (3 cycles of 100 mg/m2 Q3W) (pts at high risk). RT is standard fractionation at 2 Gy/fraction for 30, 33, or 35 fractions (60 Gy, 66 Gy, or 70 Gy) for pts at low risk or high risk or with gross residual disease, respectively. Randomization will be stratified by primary tumor site (oropharynx/oral cavity vs larynx vs hypopharynx), tumor stage (III vs IVA), and HPV p16 status (oropharynx p16–positive vs oropharynx p16–negative or larynx/hypopharynx/oral cavity). Eligible pts are adults with newly diagnosed, resectable, nonmetastatic stage III/IVA HNSCC (AJCC Cancer Staging Manual, 8th edition), evaluable tumor burden, and ECOG PS 0 or 1 who are eligible for primary surgery. Treatment will continue until disease progression, unacceptable toxicity, or decision to withdraw in both arms. Co-primary end points are major PR (≤10% invasive SCC within resected primary tumor and sampled regional lymph nodes per blinded central pathology) and event-free survival. Secondary end points include overall survival, pathological complete response, quality of life, and safety. The first radiologic imaging in arm A will occur after 2 cycles of pembro and before surgery. Postoperative imaging will occur in both arms 12 weeks after SOC, then every 3 months until year 3 and every 6 months thereafter. Recruitment is ongoing; estimated enrollment is ∼700 pts.
Clinical trial identification
NCT03765918.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
E. Cohen: Advisory / Consultancy: Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Incyte; MSD; Merck. R. Uppaluri: Advisory / Consultancy, Research grant / Funding (self): Merck. N. Lee: Advisory / Consultancy: Merck, Merck Serono, Pfizer, Sanofi; Spouse / Financial dependant, Spouse Stockholder: AstraZeneca. W. Westra: Advisory / Consultancy, Travel / Accommodation / Expenses: Merck. R. Haddad: Advisory / Consultancy: Celgene, Merck, Eisai, Bristol-Myers Squibb, AstraZeneca, Pfizer, Loxo, Genentech, Immunomic Therapeutics; Research grant / Funding (institution): Boehringer Ingelheim, Merck, Bristol-Myers Squibb, Celgene, AstraZeneca, VentiRx, Genentech, Pfizer, Kura. C. Le Tourneau: Honoraria (self), Advisory / Consultancy: Merck Serono, Bristol-Myers Squibb, MSD, Amgen, Novartis, Nanobiotix; Travel / Accommodation / Expenses: Bristol-Myers Squibb, Amgen, MSD, Merck Serono. R. Chernock: Advisory / Consultancy: Merck, Roche. Y. Tao: Research grant / Funding (institution): Debiopharma, MSD, Pfizer; Travel / Accommodation / Expenses: MSD, Merck Serono. I. Brana: Advisory / Consultancy: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Bristol-Myers Squibb, AstraZeneca, Merck Serono; Research grant / Funding (self): AstraZeneca, Bristol-Myers Squibb, Celgene, Gliknik, GlaxoSmithKline, Janssen Oncology, Kura, Merck Sharp & Dohme, Novartis, Orion Pharma GmbH, Pfizer; Travel / Accommodation / Expenses: AstraZeneca Spain, Merck Serono. J.Y. Ge: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. R. Swaby: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. B. Bidadi: Full / Part-time employment: Merck. D. Adkins: Advisory / Consultancy: Pfizer, Eli Lilly, Merck, Celgene; Travel / Accommodation / Expenses: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract